The McNair Group

Oseberg, LLC is a software company specializing in analytics solutions for the oil and gas industry, focusing on the Oklahoma and Texas markets. Founded in 2009 and headquartered in Oklahoma City, Oklahoma, with an additional office in New Orleans, Louisiana, Oseberg develops a software-as-a-service (SaaS) platform that aggregates public regulatory and county-level data. This platform allows users to search, map, mine, and conduct statistical analysis on a wide array of data, facilitating the discovery of leasing, drilling, and acquisition opportunities. Among its product offerings are atla, an energy data and mapping engine; soI, a data search tool; oseFrac, which organizes fracturing data; dataStream, which integrates with business intelligence systems; and oseberg map services. Oseberg’s solutions aim to enhance the efficiency and effectiveness of oil and gas exploration and operations by providing high-quality, normalized data.

Xeris Biopharma Holdings is a specialty pharmaceutical company focused on developing and commercializing innovative therapies for patients in endocrinology, neurology, and gastroenterology. The company utilizes its proprietary formulation technologies, XeriSol and XeriJect, to create ready-to-use, liquid-stable injectables that facilitate subcutaneous and intramuscular delivery of various therapeutic agents. Xeris offers three commercially available products: Gvoke, a liquid glucagon for severe hypoglycemia; Keveyis, the first FDA-approved treatment for primary periodic paralysis; and Recorlev, approved for endogenous hypercortisolemia in adults with Cushing's Syndrome. Xeris Biopharma's formulation platforms aim to improve patient and caregiver ease of use by eliminating reconstitution, ensuring long-term stability at room temperature, and reducing injection volume, thereby enhancing healthcare delivery and potentially lowering costs for the healthcare system. The company is also advancing a pipeline of development programs to expand its product offerings.